RecruitingNCT06836219

Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario

Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario: A Retrospective and Prospective, Multicenter, Two Cohorts Study

Sponsor

Consorzio Oncotech

Enrollment

300 participants

Start Date

Sep 13, 2024

Study Type

OBSERVATIONAL

Conditions

Ovarian Cancer

Summary

This is a retrospective and prospective, multicenter, observational, two-cohorts study aimed to evaluate clinical outcomes and safety of patients diagnosed with advanced high grade ovarian cancer whose tumor was tested for the homologous recombination (HR) status using a validated HR deficiency test between January 2021 and January 2026. * Cohort A: Homologous Recombination Deficient (HRD) ovarian cancer patients treated with Olaparib plus Bevacizumab as maintenance therapies after partial or complete response to first line platinum-based chemotherapy. * Cohort B: Homologous Recombination Proficient (HRP) ovarian cancer patients treated as for standard clinical practice at clinician's choice.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This real-world study tracks outcomes in women with advanced ovarian, fallopian tube, or peritoneal cancer based on their tumor's DNA repair status (called HRD — homologous recombination deficiency) and whether they were treated with matched therapies. The goal is to understand which patients benefit most from which treatments. **You may be eligible if...** - You are a woman 18 or older - You have been diagnosed with high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer - You have had HRD testing performed (a specific DNA repair test) between January 2021 and January 2026 - You received treatment matched to your HRD test result (details vary by cohort) **You may NOT be eligible if...** - You have not had HRD testing - Your cancer type does not match the study criteria - You did not receive the specified treatment regimens Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(21)

Istituto Tumori "Giovanni Paolo II" I.R.C.C.S.

Bari, BA, Italy

Azienda Ospedaliero Universitaria di Bologna - Policlinico S.Orsola-Malpighi

Bologna, BO, Italy

Azienda Ospedaliera S.Croce e Carle Cuneo

Cuneo, CN, Italy

Azienda Ospedaliera per l'emergenza Cannizzaro

Catania, CT, Italy

IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"

Meldola, FC, Italy

Azienda Ospedaliero Universitario Careggi

Florence, FI, Italy

IRCCS Policlinico San Martino

Genova, GE, Italy

Fondazione IRCCS San Gerardo dei Tintori (Monza)

Monza, MB, Italy

Università Vita-Salute San Raffaele (IRCCS San Raffaele - Milano)

Milan, MI, Italy

Istituto Nazionale Tumori (INT) - Milano

Milan, MI, Italy

Istituto Oncologico Veneto (IOV)

Padova, PD, Italy

Ospedale S. Maria della Misericordia

Perugia, PG, Italy

Centro di riferimento oncologico - CRO di Aviano

Aviano, PN, Italy

Istituto Nazionale Tumori Regina Elena - Roma

Roma, RM, Italy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Roma, RM, Italy

Ospedale San Paolo - ASL2 - Savona

Savona, SV, Italy

Ospedale Mauriziano Umberto I

Torino, TO, Italy

Azienda sanitaria universitaria Friuli Centrale (ASU FC)

Udine, UD, Italy

Azienda Ulss 3 Serenissima

Mestre, VE, Italy

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale

Naples, Italy

Università degli Studi di Napoli "Federico II"

Naples, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06836219

Related Trials

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT0702362782 locations

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

NCT034128771 location

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT07214779162 locations

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467167 locations

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

NCT073711041 location